MICROBIOTIX, INC. Worcester, MA, USA
Microbiotix’s unique approach to targeting drug-resistant Gram-negative bacteria focuses on bacterial virulence, specifically the type III secretion system of Pseudomonas aeruginosa. The novel inhibitors, discovered by Microbiotix scientists, have been shown to reverse the pathogen’s disruption of the host innate immune response to infection and are not subject to efflux or existing antibiotic resistance mechanisms. Microbiotix’s lead program, MBX-400, is a novel potent nucleoside dual DNA polymerase/kinase inhibitor for the management of cytomegalovirus disease in transplant patients and is Phase 2 ready.
Current Development Stage: Lead Optimization
CARB-X Investment: Initial investment of up to $1.6m with potential option payments up to $1.6m
Initial CARB-X Investment Date: April 1, 2017